Ranibizumab for age-related macular degeneration - horizon scanning review
NHSC
Record ID 32005000260
English
Authors' objectives:
This study aims to assess the effectiveness of ranibizumab for age-related macular degeneration.
Authors' recommendations:
Ranibizumab (Lucentis), an anti-angiogenic anti-VEGF antibody in trials for predominantly classic, minimally classic and occult subfoveal choroidal neovascularisation (CNV) associated with wet-type age-related macular degeneration (AMD). Ranibizumab is administered as monthly intravitreal injections. The company report that complete, but unpublished phase II trials have shown ranibizumab led to a continued improvement in visual acuity between 3 and 6-month time-points when compared to current treatment in a randomised trial. The company state there are two ongoing phase III studies of ranibizumab versus placebo and versus verteporfin photodynamic therapy (PDT).
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Macular Degeneration
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.